Ved optitrering skal dosis afpasses mellem maksimal terapeutisk virkning og uacceptable bivirkninger.
In view of the extension of indication to Restless Legs Syndrome, the periodic safety update reports will be submitted every six months during two years, once a year for the following two years and thereafter at three-yearly intervals.